Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
New York City, NY: March 16, 2020 - Published via (Wired Release) - Recent Research and Future Market Potential of Gas Nitriding Furnace Market in Global Industry: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and info...
– In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline ® Depot (lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IP...
- Studies include quantitative findings from patients and healthcare professionals, and new perspectives on somatostatin analogs in the management of neuroendocrine tumors (NETs) and acromegaly - Multinational PRESTO (nurse preference) study results simultaneously published as open access i...
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 Canada NewsWire NEW YORK, March 10, 2020 NEW YORK , March 10, 2020 /CNW/ - Deutsche Bank today announced the lineup for its Deposi...
Ipsen S.A. (IPSEY) Q4 2019 Earnings Conference Call February 13, 2020 8:30 AM ET Company Participants Aymeric Le Chatelier - Chief Executive Officer Conference Call Participants Michael Leuchten - UBS Ltd. Diana H W Na - Goldman Sachs Matthew Weston - Credit Suisse Delphi...
The following slide deck was published by Ipsen S.A. in conjunction with their 2019 Q4 earnings Read more ...
Ipsen S.A. ( OTCPK:IPSEY ): FY Non-GAAP EPS of €6.74; GAAP EPS of -€0.61. Revenue of €2.58B (+16.2% Y/Y) Press Release More news on: Ipsen S.A., Earnings news and commentary, Healthcare stocks news,
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2019. Group sales growth of 15.8% as reported or 14.8% at constant currency and scope of consolidation 1 , driven by Speci...
Exelixis (NASDAQ: EXEL ) announces positive results from an open-label Phase 1b clinical trial, COSMIC-021 , evaluating the combination of Cabometyx (cabozantinib) and Roche's Tecentriq (atezolizumab) in patients with solid tumors. More news on: Exelixis, Inc., Ipsen S.A., Healthcare st...
Revance Therapeutics (NASDAQ: RVNC ) has filed a marketing application in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for injection) for the treatment of moderate-to-severe glabellar (frown) lines. The agency's action date is November 25. More news on: Revance Therapeutics, In...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...